<DOC>
	<DOCNO>NCT01808274</DOCNO>
	<brief_summary>The purpose study assess safety device success Edwards CENTERA Transcatheter Heart Valve ( THV ) System patient symptomatic , severe aortic stenosis indicate aortic valve replacement .</brief_summary>
	<brief_title>Safety Performance Study Edwards CENTERA Self-Expanding Transcatheter Heart Valve</brief_title>
	<detailed_description>This non-randomized , prospective , multi-center safety device success study . 34 patient enrol 4 participate investigational center Europe . Patient participation last minimum 5 year . Patients assess follow interval : baseline , discharge , 30 day , 6 month , 1 year annually thereafter 5 year</detailed_description>
	<criteria>1 . High surgical risk : STS Score ≥ 8 , EuroSCORE ≥ 15 . 2 . NYHA ≥ II . 3 . Heart team ( include examine cardiac surgeon ) agree eligibility include assessment TAVR appropriate . 4 . Study patient adult legal consent age . 5 . Study patient provide write informed consent comply study procedure followup visit . 1 . Acute myocardial infarction ≤ 30 day intend treatment . 2 . Untreated clinically significant coronary artery disease require revascularization . 3 . Aortic valve congenital unicuspid congenital bicuspid valve . 4 . Mixed aortic valve disease ( predominant aortic regurgitation ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Transcatheter Aortic Valve Replacement</keyword>
	<keyword>Aortic Stenosis</keyword>
</DOC>